Invitrogen Corporation (IVGN), Clontech (BDX) Reach Settlement in Patent Litigation  
5/30/2007 3:08:09 AM

CARLSBAD, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN) and Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., have jointly announced a confidential settlement of their patent litigation, following a jury decision last week in federal district court in Greenbelt, Maryland. As part of the settlement, Clontech has agreed that Invitrogen Patent Nos. 5,244,797, 5,668,005, 6,063,608, and 5,405,776 on RNase H minus reverse transcriptase (RT) are valid and enforceable. Clontech has discontinued sales of its RNase H minus RT products, including its PowerScript products, for the life of the patents. The parties did not disclose other details of their agreement.